Jenex Announces Exciting Updates for InterceptCS, Fast Cold Sore Treatment for Fiscal Year 2016

Toronto, Ontario--(Newsfile Corp. - April 12, 2016) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company").

The Jenex Corporation is capitalizing on the corporation's current momentum to end FY2016's Q4 with these exciting news stories and developments in the pipeline.

Jenex Updates on Renewed Digital Marketing

Jenex is pleased to announce the implementation of a renewed digital marketing effort, focusing on social media channels, online advertising, and a dynamic renewal of the corporation's website and online presence. Through stronger engagement with the online marketplace, Jenex is connecting customers with devices they need for clear beautiful skin. Customers can now buy product easier than ever before by visiting the new InterceptCS website:

InterceptCS — Fast Cold Sore Treatment — Updates and News — http://www.interceptcs.com

Jenex is also pleased to announce exciting news for our Intercept CS and Therapik products: Jenex's research and development team has been hard at work developing the future of the corporation's line of effective, non-invasive and pain-free skin care devices. Working with top designers, Jenex is constantly striving for the pinnacle of aesthetics, ergonomics and portability. We believe that healthy skincare should fit easily into your lifestyle, and our products are evolving to reflect that. The sleeker, more compact version 2.0 of our Intercept CS and Therapik products are coming!

World Health Organization ("WHO") HSV-1 Research

According to a recent study by the World Health Organization, an estimated 3.7 billion people under the age of 50 have the virus, known as HSV-1, globally. The WHO further estimates that in the Americas, 49 percent of women, or 178 million women, and 39 percent of men, or 142 million men, have HSV-1 virus. In Asia, close to 60 percent of the population is estimated to have HSV-1 infection. In Africa, the numbers are even more staggering: the WHO estimates that 87% of the population have the HSV-1 virus.

HSV-1 can be spread between individuals through commonplace interactions such as eating from the same utensils, sharing lip balm, or kissing. An individual infected with HSV-1 can suffer from painful blistering sores around the mouth.

HSV-1 sores can be unsightly and embarrassing, but can be prevented at the first sign of outbreak if treated with Jenex's InterceptCS device. Jenex's InterceptCS cold sore treatment system remains the only product that is certified in Canada to make a prevention claim for HSV-1 outbreaks.

The Intercept CS's breakthrough proprietary technology uses heat treatment to penetrate deep into the skin cells infected by the HSV-1 virus. The treatment causes a microbial heat shock response, where the targeted viral cells release heat shock proteins that cause them to essentially self-destruct. This creates a powerful antiseptic effect that promotes healing and can prevent or reduce the length of a HSV-1 breakout while being gentle enough to not burn or irritate the skin.

Jenex looks forward to providing exciting future updates soon.

For further information please contact:

Forward Looking Statements

This press release contains forward-looking statements. More particularly, this press release contains statements which may include the timing of closing the offering, the anticipated use of proceeds and the receipt of the required approvals. The forward-looking statements are based on certain expectations and assumptions made by Jenex. Although Jenex believes that those expectations and assumptions are reasonable, undue reliance should not be placed on the forward-looking statements because Jenex can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors and risks. In addition to other risks, the closing of the offering could be delayed if Jenex is not able to obtain necessary approvals when planned and the offering will not be completed at all if approvals are not obtained or some other condition to the closing is not satisfied. Accordingly, there is a risk that the offering will not be completed within the anticipated time or at all. The intended use of the net proceeds of the offering by Jenex might change if Jenex determines that it would be in the best interests of Jenex to use the proceeds for some other purpose. The forward-looking statements contained in this press release are made as of the date hereof. Jenex disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES